HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Ligand Pharmaceuticals (NASDAQ: LGND) and maintained a price target of $358. This endorsement suggests continued confidence in the company's performance and potential for growth.